Table 1. Clinical outcomes for OPG following RT.
| Study | Patients (n) | OPG | RT | Total dose | Definition of progression | PFS | OS | |
|---|---|---|---|---|---|---|---|---|
| Only OPG | ||||||||
| Tao et al. [11] | 29 | 29 (100%) | X-ray | 54 Gy | Radiologic assessment | 10 yr 89% | 10 yr 100% | |
| Cappelli et al. [12] | 53 | 53 (100%) | X-ray | 50–55 Gy | Visual symptom | 10 yr 66% | 10 yr 83% | |
| Radiologic assessment | ||||||||
| Grabenbauer et al. [24] | 25 | 25 (100%) | X-ray | 45–60 Gy | Radiologic assessment | 10 yr 69% | 10 yr 94% | |
| Combs et al. [15] | 15 | 15 (100%) | X-ray | 52.2 Gy | Radiologic assessment | 5 yr 72% | 5 yr 90% | |
| Tsang et al. [9] | 89 | 89 (100%) | X-ray | 54 Gy | Radiologic assessment | 10 yr 62%–68% | 10 yr 92%–98% | |
| Secondary malignancy | ||||||||
| Acharya et al. [16] | 41 | 41 (100%) | X-ray | 54 Gy | Radiologic assessment | 5 yr 84% | - | |
| Mixed OPG and other low-grade glioma | ||||||||
| Marcus et al. [13] | 81 | 37 (46%) | X-ray | 52.2 Gy | Radiologic assessment | 5 yr 83%, 8 yr 65% | 5 yr 98%, 8 yr 82% | |
| Oh et al. [4] | 181 | 62 (34%) | X-ray | 54–57 Gy | Neurologic symptom | 8 yr 39% | 8 yr 94% | |
| Radiologic assessment | ||||||||
| Raikar et al. [5] | 17 | 6 (35%) | X-ray | 50–54 Gy | Radiologic assessment | 3 yr 69%, 10 yr 46% | 10 yr 100% | |
| Cherlow et al. [10] | 85 | 37 (44%) | X-ray | 54 Gy | Radiologic assessment | 3 yr 77%, 5 yr 71% | 3 yr 94%, 5 yr 93% | |
| Greenberger et al. [25] | 32 | Unknown | Proton | 52.5 GyRBE | Radiologic assessment | 8 yr 83% | 8 yr 100% | |
| Indelicato et al. [14] | 174 | 101 (58%) | Proton | 54 GyRBE | Radiologic assessment | 5 yr 88% | 5 yr 93% | |
OPG, optic pathway glioma; RT, radiation therapy; PFS, progression-free survival; OS, overall survival. RBE, relative biological effectiveness